Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod for Moderate to Severe Ulcerative Colitis (Real-world, AT-naïve, China)
ChiCTR2600127796Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of etrasimod in autoimmune colitis, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: clinical remission. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ChiCTR2600127796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127796.